Dernières nouvelles pour MDxHealth (NASDAQ:MDXH) Stock

MDxHealth

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

MDxHealth SA

Medx Health Corp

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and lowers the price target from $19 to $18.

News

Price Target

Analyst Ratings

TVTX

B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18

Insider Trades

ONCO

Altos Venture Reported A 32.5% Stake In Onconetix As Of September 24 In A 13D Filing On Thursday

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Armada Hoffler Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>)</h3>
<ul>
<li>On Sept. 26, Armada Hoffler Properties announced the pricing of an underwritten offering of 9 million shares of its stock for the total proceeds of approximately $94.5 million. The company's stock fell around 12% over the past five days and has a <a href="https://www.benzinga.com/quote/AHH">52-week low of $9.81</a>.</li>
<li>RSI Value: 29.97</li>
<li>AHH Price Action: Shares of Armada Hoffler Properties fell 8.9% to close at $10.80 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1">latest AHH news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041219/image-218.png" alt="" class="wp-image-569278" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041219/image-218.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041219/image-218-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041219/image-218-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">La Rosa Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Thursday, La Rosa Holdings announced that it has entered into an amendment with its noteholder to restructure debt under three outstanding notes issued to the holder in February, April, and July 2024. As part of the amendment, the Company agreed to repay the holder $200,000 of the debt under the notes, and all principal and interest payments under the notes have been deferred until Feb. 1, 2025. The company's stock fell around 36% over the past month. It <a href="https://www.benzinga.com/quote/LRHC">has a 52-week low</a> of $0.52.</li>
<li>RSI Value: 29.83</li>
<li>LRHC Price Action: Shares of La Rosa gained 1% to close at $0.68 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1">trend in LRHC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041345/image-219.png" alt="" class="wp-image-569280" style="width:718px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041345/image-219.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041345/image-219-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27041345/image-219-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Creative Media &amp; Community Trust Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>)</h3>
<ul>
<li>On Aug. 8, Creative Media posted better-than-expected quarterly results. &#8220;Our core FFO improved from the first quarter of 2024 due to improved net operating income across all of our real estate segments &#8211; multifamily, office and hotel,&#8221; said David Thompson, Chief Executive Officer of Creative Media &amp; Community Trust Corporation. &#8220;Our goal is to strengthen our balance sheet and improve our cash flow. In order to achieve this goal, we continue to actively evaluate asset sales and other ways to reduce both our recourse debt and overall debt.&#8221; The company's shares fell around 63% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CMCT">low of $0.68.</a></li>
<li>RSI Value: 14.80</li>
<li>CMCT Price Action: Shares of Creative Media &amp; Community Trust gained 3.9% to close at $0.72 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092724&amp;t=be2bearmibe3na1">breakout in CMCT shares</a>.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41055695/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

CMCT

LRHC

Top 3 Real Estate Stocks That Are Preparing To Pump This Month

B of A Securities analyst Ruplu Bhattacharya maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Buy and raises the price target from $135 to $150.

B of A Securities Maintains Buy on Jabil, Raises Price Target to $150

TNXP

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent Covering The Subcutaneous Delivery Of FDA-approved Zembrace Symtouch To Treat Migraines; New Patent Expected To Provide Market Exclusivity Into 2036

B of A Securities analyst Wamsi Mohan downgrades HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) from Buy to Neutral and maintains the price target from $37 to $37.

Downgrades

B of A Securities Downgrades HP to Neutral, Maintains Price Target to $37

JMP Securities analyst Steven Delaney maintains Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) with a Market Outperform and raises the price target from $16 to $16.5.

JMP Securities Maintains Market Outperform on Arbor Realty Trust, Raises Price Target to $16.5

Concord Medical Reports Financial Results For 1H: Revenues Fell 23.1% YoY To $30.1M

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $172 to $150.

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $150

The Company will also present additional results from the Phase&nbsp;2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology&ndash;Head and Neck Surgery (AAO-HNS), taking place September 28 - October 1 in Miami.

LYRA

Lyra Therapeutics Announced That The Company Will Present Results From The Phase 3 ENLIGHTEN 1 Study For LYR-210, The Company's Lead Product Candidate For CRS

Baird analyst David Koning maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Neutral and raises the price target from $350 to $370.

Baird Maintains Neutral on Accenture, Raises Price Target to $370

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life. 
&nbsp;
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government&#39;s Healthy China 2030 public health plan.
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.

REGN

Regeneron Pharmaceuticals And Sanofi Today Announced That  National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease

Baird analyst Ben Kallo maintains HA Sustainable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>) with a Outperform and raises the price target from $36 to $47.

Hannon Armstrong Sustainable Infrastructure Capital

HASI

Baird Maintains Outperform on HA Sustainable, Raises Price Target to $47

Stephens &amp; Co. analyst Tommy Moll maintains ESCO Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) with a Overweight and raises the price target from $135 to $145.

Stephens & Co. Maintains Overweight on ESCO Technologies, Raises Price Target to $145

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in&nbsp;Japan&nbsp;for the FARAPULSE&trade; Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System, which is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), is a novel alternative to standard-of-care thermal ablation treatment.

Boston Scientific Receives Japanese Regulatory Approval For The FARAPULSE Pulsed Field Ablation System, Which Is Indicated For Isolation Of Pulmonary Veins In Treatment Of Paroxysmal Atrial Fibrillation

Baird analyst Ben Kallo maintains MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) with a Outperform and raises the price target from $20 to $25.

Baird Maintains Outperform on MP Materials, Raises Price Target to $25

Earnings

MITQ

Moving iMage Technologies Q4 Adj EPS $(0.04) Down From $(0.02) YoY, Sales $6.30M Up From $5.80M YoY

Stephens &amp; Co. analyst Mike Scialla maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Overweight and raises the price target from $74 to $76.

MTDR

Stephens & Co. Maintains Overweight on Matador Resources, Raises Price Target to $76

Keybanc analyst Michael Leshock maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Overweight and raises the price target from $8 to $11.

RKLB

Keybanc Maintains Overweight on Rocket Lab USA, Raises Price Target to $11

On September 26, 2024, Uber Technologies, Inc. (the &ldquo;Company&rdquo;) entered into a Credit Agreement (the &ldquo;Credit Agreement&rdquo;), among the Company, the lenders party thereto, the letter of credit issuers party thereto and Bank of America, N.A., as administrative agent. The Credit Agreement replaces the Company&rsquo;s existing Revolving Credit Agreement, dated as of June 26, 2015, among the Company, certain subsidiary guarantors from time to time party thereto, the lenders party thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (as amended to date,&nbsp;the &ldquo;Existing Credit Agreement&rdquo;), which was terminated effective September 26, 2024.
&nbsp;
The Credit Agreement provides for $5.0 billion in aggregate amount of commitments for senior unsecured revolving loans, which will mature on September 26, 2029 unless otherwise extended in accordance with the terms of the Credit Agreement. The Credit Agreement provides that the Company may obtain, subject to the satisfaction of customary conditions, loans in U.S. Dollars or certain alternate currencies. Proceeds from any borrowings under the Credit Agreement may be used for general corporate purposes. The Credit Agreement is unsecured and is not guaranteed by any subsidiary of the Company.
&nbsp;
Loans under the Credit Agreement will bear interest, at the option of the Company, at either the term SOFR rate (determined in accordance with the Credit Agreement) plus an initial margin of 1.00% per annum or the base rate (determined in accordance with the Credit Agreement) plus an initial margin of 0.00% per annum. The Credit Agreement has a commitment fee, which will initially accrue at a rate of 0.125% per annum, on the actual daily undrawn amount of the aggregate commitments of the lenders in respect to the Credit Agreement. The applicable margin over the term SOFR rate and the base rate, as well as the commitment fee, will fluctuate based upon the ratings of the Company&rsquo;s non-credit enhanced senior unsecured long-term debt by Standard &amp; Poor&rsquo;s Financial Services LLC, Moody&rsquo;s Investors Service, Inc. or Fitch Ratings Ltd.
&nbsp;
The Credit Agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default. Negative covenants include, among others, certain limitations on the incurrence of liens securing indebtedness by the Company and its material subsidiaries and the incurrence of indebtedness by the Company&rsquo;s material subsidiaries. In addition, the Credit Agreement requires that the Company maintain a ratio of consolidated adjusted earnings before interest, taxes, depreciation and amortization to consolidated interest expense of not less than 3.00 to 1.00, as more fully described in the Credit Agreement. The following events are considered &ldquo;events of default&rdquo; under the Credit Agreement: default in the payment of principal of any loan or any letter of credit obligation; default in the payment of any interest on any loan or on any letter of credit obligation, any fee due or any other amount payable thereunder and such default continues for a period of five business days; failure to comply with specified covenants; material misrepresentations; certain defaults by the Company or any of the Company&rsquo;s material subsidiaries with respect to indebtedness for borrowed money in an amount exceeding $300 million; certain events of bankruptcy, insolvency or reorganization of the Company, any of the Company&rsquo;s material subsidiaries (as defined in the Credit Agreement) or any of the Company&rsquo;s significant subsidiaries (as defined in the Credit Agreement); certain judgment defaults against the Company or any of the Company&rsquo;s material subsidiaries in an amount exceeding $300 million; the occurrence of certain ERISA events; and the occurrence of any change of control (as defined in the Credit Agreement). If certain bankruptcy and insolvency-related events of default occur any outstanding obligations under the Credit Agreement may be declared immediately due and payable and the commitments may be terminated. If an event of default, other than certain bankruptcy insolvency-related events of default, occur and are not cured within applicable grace periods or waived, any outstanding obligations under the Credit Agreement may be declared immediately due and payable and the commitments may be terminated.
&nbsp;
At closing, approximately $413 million of letters of credit have been issued under the Credit Agreement, transitioned from outstanding letters of credit under the Existing Credit Agreement, but no borrowings have been drawn.

UBER

Uber Technologies Enters A $5B Unsecured Revolving Credit Agreement With Bank Of America, Replacing Its Previous Credit Facility; The Agreement Will Mature On September 26, 2029

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on MDxHealth (MDXH – Research Report), with a price target of $8.00....

Strong Buy Rating for MDxHealth: Robust Revenue Growth and Strategic Value Proposition

MDxHealth SA GAAP EPS of -$0.42, revenue of $22.16M beats by $1.07M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MDxHealth (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdxh-stock-quote/">MDXH</a>) just reported results for the second quarter of 2024.<ul><li>MDxHealth reported earnings per share of -42 cents. This was below the analyst estimate for EPS of -26 cents.</li><li>The company reported revenue of $22.16 million.</li><li>This was 9.59% better than the analyst estimate for revenue of $20.22 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mdxh-stock-earnings-mdxhealth-for-q2-of-2024/">MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024

MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript

Piper Sandler analyst Jason Bednar maintained a Buy rating on MDxHealth (MDXH – Research Report) today and set a price target of $8.00. The company...

MDxHealth (MDXH) Receives a Buy from Piper Sandler

BTIG analyst Mark Massaro has reiterated their bullish stance on MDXH stock, giving a Buy rating yesterday. Mark Massaro has given his Buy rating d...

MDxHealth: A Strong Buy on Robust Growth and Undervaluation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MDxHealth (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdxh-stock-quote/">MDXH</a>) just reported results for the second quarter of 2024.<ul><li>MDxHealth reported earnings per share of -42 cents. This was below the analyst estimate for EPS of -26 cents.</li><li>The company reported revenue of $22.16 million.</li><li>This was 9.59% better than the analyst estimate for revenue of $20.22 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/mdxh-stock-earnings-mdxhealth-for-q2-of-2024/">MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

MDxHealth

Actualités

Dernières nouvelles pour MDxHealth (NASDAQ:MDXH) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL